TP53 and neoplasm: Furthermore, to study the in vivo tumor suppressor role of shPRC1 on HCC with p53-mutant, the mouse model of HCC xenograft by HuH-7 cells was used, and the dual therapy of taxol/Ad-shPRC1 showed the best efficacy, suggesting shPRC1 increases taxol sensitivity of p53-mutant HCC cells (Fig. 5d).